Which has stronger valuation and earnings, KRYS or ONC?

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 22.87 $204.83M $7.48 40.35 BeOne Medicines $5.34B 5.73 $286.93M $4.47 62.42

Does the media prefer KRYS or ONC?

In the previous week, BeOne Medicines had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 9 mentions for BeOne Medicines and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.45 beat BeOne Medicines' score of 0.16 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RVMD or KRYS?

In the previous week, Revolution Medicines had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 17 mentions for Revolution Medicines and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.45 beat Revolution Medicines' score of 0.34 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BNTX or KRYS?

In the previous week, BioNTech had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for BioNTech and 6 mentions for Krystal Biotech. BioNTech's average media sentiment score of 0.59 beat Krystal Biotech's score of 0.45 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, INSM or KRYS?

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 37.12 -$1.28B -$5.75 N/A Krystal Biotech $389.13M 22.87 $204.83M $7.48 40.35

Is INSM or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to Insmed's net margin of -144.44%. Krystal Biotech's return on equity of 19.25% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Krystal Biotech 53.92% 19.25% 17.62%

Does the media refer more to INSM or KRYS?

In the previous week, Insmed had 10 more articles in the media than Krystal Biotech. MarketBeat recorded 16 mentions for Insmed and 6 mentions for Krystal Biotech. Insmed's average media sentiment score of 1.52 beat Krystal Biotech's score of 0.45 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, KRYS or ROIV?

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 22.87 $204.83M $7.48 40.35 Roivant Sciences $8.26M 2,499.16 -$299.77M -$0.60 N/A

Does the media refer more to KRYS or ROIV?

In the previous week, Krystal Biotech and Krystal Biotech both had 6 articles in the media. Roivant Sciences' average media sentiment score of 1.42 beat Krystal Biotech's score of 0.45 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Krystal Biotech (KRYS) Competitors

$301.82 +8.61 (+2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$299.82 -2.00 (-0.66%)

As of 07:50 PM Eastern

Compare

KRYS vs. ONC, RVMD, BNTX, INSM, and ROIV

Should you buy Krystal Biotech stock or one of its competitors? MarketBeat compares Krystal Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Krystal Biotech include BeOne Medicines (ONC), Revolution Medicines (RVMD), BioNTech (BNTX), Insmed (INSM), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Krystal Biotech compare to BeOne Medicines?

Krystal Biotech (NASDAQ:KRYS) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, BeOne Medicines had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 9 mentions for BeOne Medicines and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.45 beat BeOne Medicines' score of 0.16 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech currently has a consensus price target of $324.11, suggesting a potential upside of 7.39%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 39.78%. Given BeOne Medicines' higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech has a net margin of 53.92% compared to BeOne Medicines' net margin of 8.94%. Krystal Biotech's return on equity of 19.25% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
BeOne Medicines	8.94%	12.06%	6.69%

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35
BeOne Medicines	$5.34B	5.73	$286.93M	$4.47	62.42

Summary

Krystal Biotech beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Krystal Biotech has a net margin of 53.92% compared to Revolution Medicines' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Krystal Biotech	53.92%	19.25%	17.62%

Revolution Medicines currently has a consensus price target of $123.72, suggesting a potential downside of 20.69%. Krystal Biotech has a consensus price target of $324.11, suggesting a potential upside of 7.39%. Given Krystal Biotech's higher possible upside, analysts plainly believe Krystal Biotech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Revolution Medicines had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 17 mentions for Revolution Medicines and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.45 beat Revolution Medicines' score of 0.34 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,863.86	-$1.13B	-$7.07	N/A
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35

Summary

Krystal Biotech beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Krystal Biotech has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.89	-$1.29B	-$5.88	N/A
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to BioNTech's net margin of -44.39%. Krystal Biotech's return on equity of 19.25% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Krystal Biotech	53.92%	19.25%	17.62%

BioNTech presently has a consensus target price of $129.56, suggesting a potential upside of 46.48%. Krystal Biotech has a consensus target price of $324.11, suggesting a potential upside of 7.39%. Given BioNTech's higher probable upside, research analysts plainly believe BioNTech is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BioNTech had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for BioNTech and 6 mentions for Krystal Biotech. BioNTech's average media sentiment score of 0.59 beat Krystal Biotech's score of 0.45 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of BioNTech shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BioNTech and Krystal Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Insmed (NASDAQ:INSM) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

86.3% of Krystal Biotech shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Insmed currently has a consensus price target of $210.95, suggesting a potential upside of 103.11%. Krystal Biotech has a consensus price target of $324.11, suggesting a potential upside of 7.39%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	37.12	-$1.28B	-$5.75	N/A
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35

Krystal Biotech has a net margin of 53.92% compared to Insmed's net margin of -144.44%. Krystal Biotech's return on equity of 19.25% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Insmed had 10 more articles in the media than Krystal Biotech. MarketBeat recorded 16 mentions for Insmed and 6 mentions for Krystal Biotech. Insmed's average media sentiment score of 1.52 beat Krystal Biotech's score of 0.45 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Insmed beats Krystal Biotech on 9 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Krystal Biotech (NASDAQ:KRYS) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Krystal Biotech has a net margin of 53.92% compared to Roivant Sciences' net margin of -3,629.19%. Krystal Biotech's return on equity of 19.25% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Krystal Biotech and Krystal Biotech both had 6 articles in the media. Roivant Sciences' average media sentiment score of 1.42 beat Krystal Biotech's score of 0.45 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech currently has a consensus target price of $324.11, suggesting a potential upside of 7.39%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 17.04%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35
Roivant Sciences	$8.26M	2,499.16	-$299.77M	-$0.60	N/A

Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Summary

Krystal Biotech beats Roivant Sciences on 9 of the 13 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.64B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	39.20	17.93	22.30	24.19
Price / Sales	22.87	324.62	581.44	138.36
Price / Cash	40.22	116.27	42.31	57.88
Price / Book	7.18	6.63	9.84	6.72
Net Income	$204.83M	$24.20M	$3.57B	$337.19M
7 Day Performance	-1.57%	-3.24%	-1.16%	0.48%
1 Month Performance	13.45%	0.53%	3.85%	5.07%
1 Year Performance	130.56%	47.24%	27.40%	34.25%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	2.8882 of 5 stars	$301.82 +2.9%	$324.11 +7.4%	+133.9%	$8.64B	$389.13M	40.35	210	Analyst Forecast
ONC BeOne Medicines	4.3801 of 5 stars	$310.25 flat	$389.15 +25.4%	+11.7%	$34.04B	$5.34B	69.41	12,000	Analyst Forecast
RVMD Revolution Medicines	2.2093 of 5 stars	$151.56 flat	$111.35 -26.5%	+272.2%	$32.22B	$11.58M	N/A	250	Analyst Forecast Analyst Revision
BNTX BioNTech	3.6722 of 5 stars	$92.14 flat	$128.44 +39.4%	-21.2%	$23.30B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7586 of 5 stars	$106.24 flat	$210.95 +98.6%	+44.7%	$23.03B	$606.42M	N/A	1,664	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. ONC, RVMD, BNTX, INSM, and ROIV

How does Krystal Biotech compare to BeOne Medicines?

Summary

How does Krystal Biotech compare to Revolution Medicines?

Summary

How does Krystal Biotech compare to BioNTech?

Summary

How does Krystal Biotech compare to Insmed?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. ONC, RVMD, BNTX, INSM, and ROIV

How does Krystal Biotech compare to BeOne Medicines?

Which has more volatility & risk, KRYS or ONC?

Does the media prefer KRYS or ONC?

Do analysts rate KRYS or ONC?

Do institutionals & insiders believe in KRYS or ONC?

Is KRYS or ONC more profitable?

Which has stronger valuation and earnings, KRYS or ONC?

Summary

How does Krystal Biotech compare to Revolution Medicines?

Is RVMD or KRYS more profitable?

Do analysts recommend RVMD or KRYS?

Does the media favor RVMD or KRYS?

Which has more volatility and risk, RVMD or KRYS?

Do institutionals and insiders hold more shares of RVMD or KRYS?

Which has stronger valuation and earnings, RVMD or KRYS?

Summary

How does Krystal Biotech compare to BioNTech?

Which has stronger earnings and valuation, BNTX or KRYS?

Which has more risk and volatility, BNTX or KRYS?

Is BNTX or KRYS more profitable?

Do analysts prefer BNTX or KRYS?

Does the media favor BNTX or KRYS?

Do insiders and institutionals hold more shares of BNTX or KRYS?

Summary

How does Krystal Biotech compare to Insmed?

Do insiders & institutionals hold more shares of INSM or KRYS?

Do analysts prefer INSM or KRYS?

Which has higher earnings and valuation, INSM or KRYS?

Is INSM or KRYS more profitable?

Does the media refer more to INSM or KRYS?

Which has more risk & volatility, INSM or KRYS?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Is KRYS or ROIV more profitable?

Does the media refer more to KRYS or ROIV?

Do analysts prefer KRYS or ROIV?

Do institutionals and insiders hold more shares of KRYS or ROIV?

Which has preferable earnings & valuation, KRYS or ROIV?

Which has more risk and volatility, KRYS or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools